Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $7.50.

Several equities analysts have weighed in on the company. Leerink Partners dropped their target price on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, July 2nd. Wells Fargo & Company started coverage on shares of Pyxis Oncology in a research note on Monday, August 3rd. They issued an “overweight” rating and a $12.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Tuesday. Weiss Ratings downgraded shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Finally, Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th.

Key Stories Impacting Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright improved its earnings forecasts across multiple periods, including FY2026 EPS to a loss of $1.08 from $1.10, FY2027 to a loss of $0.73 from $0.88, FY2028 to a loss of $0.35 from $0.44, and FY2029 to positive $0.23 from $0.20. The revisions point to reduced expected losses and an earlier path toward profitability. HC Wainwright Reaffirms Buy Rating for Pyxis Oncology
• Positive Sentiment: The analyst also raised several quarterly forecasts, including Q1–Q3 2027 EPS to losses of $0.18 from prior estimates ranging from $0.22 to $0.27, and Q4 2027 to a loss of $0.19 from $0.23. These changes support expectations for improving cost control or operating performance.
• Neutral Sentiment: Despite the upgrades, Pyxis remains unprofitable, with consensus current-year EPS of approximately negative $1.22. The stock has a market capitalization near $195 million, making it highly sensitive to clinical, financing, and analyst-estimate changes.
• Negative Sentiment: The FY2030 EPS estimate reduction introduces a longer-term cautionary note and partially offsets the improved 2026–2029 forecasts. Investors may interpret the revision as uncertainty about the durability or timing of Pyxis Oncology’s eventual profitability.

Pyxis Oncology Stock Down 1.3%

PYXS opened at $3.08 on Friday. Pyxis Oncology has a 52 week low of $1.03 and a 52 week high of $5.55. The business has a fifty day simple moving average of $2.70 and a 200-day simple moving average of $2.03. The firm has a market cap of $195.13 million, a P/E ratio of -2.18 and a beta of 1.31.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Sell-side analysts expect that Pyxis Oncology will post -1.21 earnings per share for the current year.

Institutional Trading of Pyxis Oncology

A number of large investors have recently modified their holdings of PYXS. Laurion Capital Management LP raised its stake in shares of Pyxis Oncology by 32.3% in the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after acquiring an additional 1,170,505 shares in the last quarter. Atle Fund Management AB acquired a new position in Pyxis Oncology during the 4th quarter worth $710,000. Bank of America Corp DE grew its stake in Pyxis Oncology by 2,690.9% during the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after purchasing an additional 593,853 shares in the last quarter. Longaeva Partners L.P. purchased a new stake in Pyxis Oncology during the 3rd quarter worth about $1,117,000. Finally, Jane Street Group LLC increased its holdings in Pyxis Oncology by 158.8% during the 4th quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after purchasing an additional 482,310 shares during the period. Hedge funds and other institutional investors own 39.07% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.